Table 2 Neuroendocrine tumor characteristics
From: Outcome of carcinoid heart syndrome in patients enrolled in the SwissNet cohort
|  | All patients, n = 23 | Group Aa, n = 4 | Group B n = 12 | Group C n = 6 |
|---|---|---|---|---|
Primary tumor site, n (%) | ||||
 Ileum/Jejunum | 12 (52) | 2 (50) | 7 (58) | 3 (50) |
 CUP | 8 (35) | 2 (50) | 5 (42) | 2 (33) |
 Pancreas | 1 (4) | 0 (0) | 0 (0) | 1 (17) |
 Caecum | 1 (4) | 0 (0) | 0 (0) | 0 (0) |
 Atypical lung carcinoid | 1 (4) | 0 (0) | 0 (0) | 1 (17) |
Diagnosis, n (%) | ||||
 Neuroendocrine carcinoma | 3 (13) | 0 (0) | 1 (8) | 2 (33) |
 Neuroendocrine tumor | 19 (82) | 4 (100) | 11 (92) | 3 (50) |
 Not known | 1 (5) | 0 (0) | 0 (0) | 1 (17) |
Functional tumor, n (%) | ||||
 Yes | 20 (87) | 3 (75) | 10 (83) | 6 (100) |
 Not known | 3 (13) | 1 (25) | 2 (17) | 0 (0) |
Type of functional tumor, n (%) | ||||
 Carcinoid | 17 (74) | 2 (50) | 8 (67) | 6 (100) |
 VIPoma | 1 (4) | 1 (25) | 0 (0) | 0 (0) |
 unknown | 5 (22) | 1 (25) | 4 (33) | 0 (0) |
Metastasis, n (%) | ||||
 Liver | 23 (100) | 4 (100) | 12 (100) | 6 (100) |
 Other site | 21 (91) | 2 (50) | 11 (92) | 6 (100) |
 Lymph Nodes | 12 (52) | 0 (0) | 9 (75)* | 5 (83)* |
 Lung | 2 (9) | 0 (0) | 1 (8) | 1 (17) |
 Bone | 11 (48) | 2 (50) | 4 (33) | 5 (83) |
 Peritoneum | 8 (35) | 1 (25) | 5 (42) | 3 (50) |
 Other | 8 (35) | 0 (0) | 4 (33) | 3 (50) |
Histology, n (%)b | ||||
 G1 | 14 (74) | 2 (50) | 9 (82) | 3 (75) |
 G2 | 5 (26) | 2 (50) | 2 (18) | 1 (25) |